The USPTO has issued a new patent to Co-Diagnostics (NASDAQ:CODX) covering its CoPrimer technology used in its COVID-19 test and other molecular assays. The patent, which builds on an earlier patent awarded in October 2018 covering certain applications of the CoPrimer molecule, applies to the physical structure of the molecule.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.